Transglutaminase 3 activates keratinocytes and participates in the inflammatory response of psoriasis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051505

Enrollment

Unknown

Registered

2021-09-24

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

psoriasis group:no

healthy control group:no

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Gender: not limited; 3. Clinical diagnosis of psoriasis (regardless of type).

Exclusion criteria

Exclusion criteria: 1. Received systemic drug therapy 1 month before enrollment, including immunosuppressants such as Tripterygium wilfordii, Acitretin, cyclophosphamide, and methotrexate; 2. Received topical drug treatment 2 weeks before enrollment, including glucocorticoid ointment, calcineurin inhibitor, topical vitamin D analog, etc.

Design outcomes

Primary

Measure	Time frame
transglutaminase 3;Ten-eleven translocation;Psoriasis area and severity index scoring;	—

Countries

China

Contacts

Public ContactYao Xu

Chinese Academy of Medical Sciences Dermatology Hospital

dryao_xu@126.com+86 13512513536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026